AstraZeneca’s acquisition of Alexion Pharmaceuticals is set to close in the third quarter after shareholders voted in favour of the deal.
Chief executive Pascal Soriot said: “The approval of the acquisition by AstraZeneca shareholders represents a significant step toward combining Alexion’s leadership in complement biology and rare diseases with AstraZeneca’s expertise in precision medicine and growing presence in immunology.
“We look forward to together advancing life-changing science and bringing even more medicines to patients globally.”
The pharmaceuticals giant announced in December 2020 that it had agreed to buy Alexion in a $39bn deal to expand its scientific presence in immunology.
